Levothyroxine formulations [Design Issues]

posted by drcampos  – Brazil, 2007-04-24 06:46 (7003 d 17:36 ago) – Posting: # 689
Views: 11,359

Dear All,

I would like to evaluate the disposition of lower dosages of levothyroxine formulations, i.e 12,5 mg and 37.5 mg (new formulations). Considering the FDA Guidance it is necessary a dose of 600 mcg for avoinding baseline effect. So, the problem is the dose (48 tablets x 12.5 mcg = 600 mcg). Does someone have experience with these studies?

Regards,

Daniel

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
399 visitors (0 registered, 399 guests [including 48 identified bots]).
Forum time: 00:23 CEST (Europe/Vienna)

Ignorance more frequently begets confidence
than does knowledge.    Charles Darwin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5